Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thermotherapy and Short Course Miltefosine for Uncomplicated Cutaneous Leishmaniasis
NCT02687971Phase 2Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Dec 2016
- Primary completion
- Aug 2019
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of miltefosine in cutaneous leishmaniasis (CL) (2 arms), sponsored by Drugs for Neglected Diseases initiative. Primary endpoint: Initial cure rate at Day 90. Started Dec 2016; status: completed.
02
Drugs
miltefosine
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT02687971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02687971.